Plaque Psoriasis: Autoimmune Cytokines, PASI Staging & Biologic Therapeutics

1. Systemic Autoimmune Pathophysiology

Psoriasis Vulgaris is a chronic immune-mediated systemic inflammatory disease affecting 2–3% of the global population. Driven primarily by the IL-23/Th17 cell axis, excessive dendritic cell stimulation causes hypersecretion of IL-17 and IL-22 cytokines, triggering rapid keratinocyte transit from basal layer to stratum corneum in just 3–5 days (compared to the normal 28-day turnover).

2. Pathognomonic Clinical Signs

• Well-Demarcated Erythematous Plaques: Salmon-pink plaques overlaid with coarse, micaceous silvery-white scales.
• Auspitz Sign: Pinpoint bleeding following removal of the adherent scale, resulting from dilated tortuous capillary loops within elongated dermal papillae.
• Koebner Phenomenon: Emergence of typical psoriatic lesions along lines of mechanical cutaneous trauma or surgical incisions.

3. PASI Staging & Systemic Therapeutics

Clinical evaluation utilizes the Psoriasis Area and Severity Index (PASI) to stratify disease severity. Severe disease (PASI > 10) benefits from modern targeted biologics (anti-IL-17 secukinumab/ixekizumab; anti-IL-23 guselkumab/risankizumab) achieving complete (PASI 90/100) cutaneous clearance in up to 80% of patients.